NCT03979378

Brief Summary

Ectopic calcification and ossification complicate many diseases, which are rare for the most part. These calcifications (or ossifications) are generally classified according to their apparent formation mechanism. Even if very different diseases can be at the origin, these calcifications (or ossifications) have as common points: an unknown physiopathology, a composition of calcium pyrophosphate for the most part and l no curative treatment validated to date. Indeed, although several reported cases suggest the potential efficacy of different treatments , none of these treatments is currently recognized as effective because of the absence of confirmation data or because of contradictory results. Sodium thiosulfate (STS) has been used for a long time as an antidote to cyanide poisoning and as a protective agent against cytotoxic side effects such as ifosphamide. More recently, STS has been reported in the treatment of renal calcification. vascular or even subcutaneous. First prospective studies on animal models and in humans seem to confirm the interest of this product in the treatment of these abnormal calcifications. For several months, a magistral preparation in the form of ointment based on STS has been developed by the pharmacy of Limoges University Hospital in order to combine the local effect of STS while avoiding the side effects of an administration of this treatment by systemic way. The first uses of this preparation appear promising and some preliminary results have already been published. The benefit / risk ratio of this approach seems to be advantageous for clinicians since preparations whose composition is close are currently validated by the FDA and the World Health Organisation for the treatment of benign pathologies such as cutaneous dermatophytes or pityriasis versicolor.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2015

Longer than P75 for all trials

Geographic Reach
1 country

7 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
4.3 years until next milestone

First Submitted

Initial submission to the registry

June 4, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 7, 2019

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

June 11, 2019

Status Verified

June 1, 2019

Enrollment Period

5 years

First QC Date

June 4, 2019

Last Update Submit

June 7, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Calcification/Ossification volume

    Percentage decrease in the volume or surface area of calcifications (or ossification) treated on imaging of the same type performed before and 6 months after dermal STS use.

    Month 6

Secondary Outcomes (4)

  • Change in aesthetic evolution from baseline at 6 month

    Day 0, Month 6

  • Change in pain from baseline at 6 month

    Day 0, Month 6

  • Change of the quality of life from baseline at 6 month

    Day 0, Month 6

  • local or general side effects

    Month 6

Eligibility Criteria

Age3 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patient with ectopic calcification / ossification

You may qualify if:

  • any patient treated with sodium thiosulfate dermally provided by the pharmacy of Limoges University Hospital.
  • availability of an objective imaging evaluation to compare the volume or surface of calcifications (or ossifications) treated (on two orthogonal incidences) before and after 6 months of treatment application.
  • consent to participation in the study signed by the patient or by one of the holders of parental authority in the case of a minor patient.

You may not qualify if:

  • calcification with concomitant cutaneous rupture which can allow an externalization of the calcium material by mechanical effects.
  • Patient with calcification secondary to one of the following pathologies:
  • diabetes
  • chronic renal failure
  • iatrogenic origin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Grenoble university hospital

Grenoble, France

RECRUITING

Kremlin Bicetre Hospital

Le Kremlin-Bicêtre, France

RECRUITING

CHU de Limoges

Limoges, France

RECRUITING

HEGP

Paris, France

RECRUITING

Lariboisière Hospital

Paris, France

RECRUITING

Necker Hospital

Paris, France

RECRUITING

Robert Debré Hospital

Paris, France

RECRUITING

MeSH Terms

Conditions

Ossification, Heterotopic

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 4, 2019

First Posted

June 7, 2019

Study Start

February 1, 2015

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

June 11, 2019

Record last verified: 2019-06

Locations